Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

Share Price is delayed by 15 minutes
Get Live Data
441.00    -6.80 (-1.52%)
Bid:
440.80
Ask:
441.20
Spread: 0.40 (0.091%)
Market Cap: £2.27b
QQ. Live PriceLast checked at - London Stock Exchange

Intraday Qinetiq Share Chart

Third Quarter Trading Update

15 Feb 2017 07:00

RNS Number : 8892W
QinetiQ Group plc
15 February 2017
 

 

 

 

QinetiQ Group plc

 

Third Quarter Trading Update

 

QinetiQ Group plc ('QinetiQ' or 'the Group') today issues a trading update for the third quarter during which it has made encouraging progress in the implementation of its strategy to drive future growth.

 

Strategy update

 

On 2 December 2016, QinetiQ was awarded a £1bn amendment to its Long Term Partnering Agreement (LTPA) with the UK Ministry of Defence (MOD) which commits approximately half of the core LTPA revenues until 31 March 2028. The Group is already delivering against its commitment to modernise UK air ranges and the Empire Test Pilots' School at MOD Boscombe Down, including the purchase of new aircraft to meet the future training needs of test pilots and aircrew.

 

On 21 December 2016, the Group agreed and completed the acquisition of Meggitt Target Systems. The business, now renamed QinetiQ Target Systems, generates 90 per cent of its revenue from outside the UK and forms part of QinetiQ's International business unit. It will be reported in the Group's Global Products division.

 

On 5 January 2017, the Dragonfire consortium - led by MBDA and including QinetiQ as well as other industry partners - was awarded a £30m programme by the UK MOD to deliver a Laser Directed Energy Weapon (LDEW) Capability Demonstrator. QinetiQ's role is to provide the high-powered laser technology for the programme and conduct trials at various ranges over land and water.

 

Trading update

 

Underlying trading for the Group was as expected during the third quarter.

 

In EMEA Services, revenue under contract for this financial year is similar to the same time last year with resilient margins. As stated previously, the division's performance as a whole is expected to remain steady this year.

 

The Group's Global Products division has shorter order cycles than EMEA Services. Revenue under contract is slightly ahead of this time last year driven by improved order inflow in QinetiQ North America, although the division's performance remains dependent on the timing and shipment of key orders.

 

Balance sheet

 

The incremental capital expenditure associated with the amendment to the LTPA contract is expected to be in the region of £10m this year.

 

The Group is completing the previously announced £50m share repurchase with £13m of the buyback remaining as at 10 Feb 2017.

 

Outlook

Overall, the Board's expectations for Group performance in the current financial year remain unchanged from those set out in QinetiQ's interim results announcement dated 17 November 2016.

 

QinetiQ will announce its preliminary annual results for the year ending 31 March 2017 on 25 May 2017.

 

ENDS

 

Notes to Editors:

 

Download the QinetiQ investor relations app for iPad and iPhone from the App Store.

 

Listed on the London Stock Exchange (LSE: QQ.L), QinetiQ is a leading science and engineering company operating primarily in the defence, security and aerospace markets. Our customers are predominantly government organisations including defence departments, as well as international customers in other targeted sectors.

 

For more information see www.QinetiQ.com

 

Follow us on twitter @QinetiQ

 

For further information please contact:

Investor relations:

David Bishop, QinetiQ

+44 (0) 7920 108675

Media relations:

Chris Barrie, Citigate Dewe Rogerson

+44 (0) 7968 727289

QinetiQ press office

+44 (0) 1252 393500

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDZLFFDLFXBBZ
Date   Source Headline
9th Aug 20227:00 amRNSDelivering growth in the US with $45m contract win
5th Aug 20226:22 pmRNSProposed Acquisition of Avantus Federal LLC
1st Aug 20223:19 pmRNSHolding(s) in Company
21st Jul 20223:18 pmRNSResult of AGM
21st Jul 20227:00 amRNSFirst Quarter Trading Update
19th Jul 20225:24 pmRNSHolding(s) in Company
12th Jul 20222:09 pmRNSHolding(s) in Company
12th Jul 20221:47 pmRNSDirector/PDMR Shareholding
29th Jun 20225:09 pmRNSDirector/PDMR Shareholding
27th Jun 202212:35 pmRNSHolding(s) in Company
15th Jun 20229:53 amRNSHolding(s) in Company
13th Jun 202212:59 pmRNSDirector/PDMR Shareholding
13th Jun 202212:28 pmRNSAnnual Financial Report
6th Jun 202210:52 amRNSHolding(s) in Company
30th May 202212:03 pmRNSNotification of Major Shareholding
23rd May 20227:00 amRNSConfirmation of Full Year Results
19th May 20227:00 amRNSPreliminary Results
18th May 20227:00 amRNSDirectorate Change
17th May 202211:24 amRNSHolding(s) in Company
16th May 20221:45 pmRNSHolding(s) in Company
10th May 202211:49 amRNSDirector/PDMR Shareholding
27th Apr 20227:00 amRNSInvestor Seminar: Delivering our global ambition
26th Apr 20221:37 pmRNSHolding(s) in Company
21st Apr 20229:15 amRNSHolding(s) in Company
20th Apr 20227:00 amRNSFourth Quarter Trading Update
12th Apr 202212:45 pmRNSDirector/PDMR Shareholding
10th Mar 202211:27 amRNSDirector/PDMR Shareholding
10th Feb 202211:52 amRNSDirector/PDMR Shareholding
10th Feb 202211:52 amRNSDirector/PDMR Shareholding
2nd Feb 20228:42 amRNSHolding(s) in Company
24th Jan 202211:12 amRNSDirector/PDMR Shareholding
19th Jan 20221:43 pmRNSHolding(s) in Company
18th Jan 20227:00 amRNSThird Quarter Trading Update
17th Jan 20227:00 amRNSAppointment of President and CEO of QinetiQ US
11th Jan 202211:43 amRNSDirector/PDMR Shareholding
5th Jan 20225:05 pmRNSDirector/PDMR Shareholding
20th Dec 20219:21 amRNSDirector Declaration
10th Dec 202112:42 pmRNSDirector/PDMR Shareholding
6th Dec 202112:16 pmRNSHolding(s) in Company
18th Nov 202111:04 amRNSDirector/PDMR Shareholding
17th Nov 202110:54 amRNSDirector/PDMR Shareholding
16th Nov 202111:24 amRNSDirector/PDMR Shareholding
11th Nov 20217:00 amRNSInterim Results
10th Nov 202112:12 pmRNSDirector/PDMR Shareholding
1st Nov 202111:43 amRNSBlock listing Interim Review
19th Oct 20219:16 amRNSHolding(s) in Company
14th Oct 20217:00 amRNSTrading Update
12th Oct 202110:43 amRNSDirector/PDMR Shareholding
10th Sep 20212:07 pmRNSDirector/PDMR Shareholding
31st Aug 20212:35 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.